General Motors on Wednesday announced that in 2022 it delivered 2.2 million vehicles in the United States, making it the biggest automaker in the country.
Toyota took the crown from GM back in 2021, but held onto it for less than two years. The Japanese automaker sold 2.1 million vehicles in 2022, which is down 9.6 percent from 2021.
Shares of Toyota were down more than 1 percent following the release on Wednesday.
GM, by comparison, saw its sales increase 2.5 percent from 2021. A big chunk of those gains came in the fourth quarter, as supply chain issues eased and sales shot up 40 percent year-over-year. Cadillac sales were up 75 percent, and GM Fleet sales jumped 101 percent.
The legacy automaker isn't resting on its laurels in 2023. GM said it plans to grow its share of the electric vehicle market with a number of battery-powered models.
"GM plans to build on this momentum in North America in 2023, growing EV market share with nine EV models on sale, including the Chevrolet Bolt EV and Bolt EUV, which was the bestselling mainstream EV series in the third and fourth quarter," the company said in a statement.
The company said it expects production of the Bolt EV and Bolt EUC to increase to more than 70,000 units this year. Sales of those models were up 64,332 percent in 2022, as GM ramped up production of its electric line.
Smoke that filled the cabin of a Delta flight as it took off from the Atlanta airport in February was so thick the led flight attendant had trouble seeing past the first row of passengers and the pilots donned oxygen masks as a precaution.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
ReturnPro CEO Sender Shamiss to discuss how his company is changing the way we make returns and how Trump's tariffs are affecting the return business. Watch!
